Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT

Conclusion
This study provides level 4 evidence that AHSCT in patients previously treated with alemtuzumab, cladribine or rituximab is safe and efficacious.

Source: Journal of Neurology, Neurosurgery and Psychiatry - July 14, 2022 Category: Neurosurgery Authors: Kvistad, S. A. S., Burman, J., Lehmann, A. K., Tolf, A., Zjukovskaja, C., Melve, G. K., Bo, L., Torkildsen, O. Tags: Open access Multiple sclerosis Source Type: research